Literature DB >> 29742910

An Overview of Animal Models Related to Schizophrenia.

Ian R Winship1, Serdar M Dursun2,3, Glen B Baker2,3, Priscila A Balista4, Ludmyla Kandratavicius5, Joao Paulo Maia-de-Oliveira3,6, Jaime Hallak3,5,7, John G Howland8.   

Abstract

Schizophrenia is a heterogeneous psychiatric disorder that is poorly treated with current therapies. In this brief review, we provide an update regarding the use of animal models to study schizophrenia in an attempt to understand its aetiology and develop novel therapeutic strategies. Tremendous progress has been made developing and validating rodent models that replicate the aetiologies, brain pathologies, and behavioural abnormalities associated with schizophrenia in humans. Here, models are grouped into 3 categories-developmental, drug induced, and genetic-to reflect the heterogeneous risk factors associated with schizophrenia. Each of these models is associated with varied but overlapping pathophysiology, endophenotypes, behavioural abnormalities, and cognitive impairments. Studying schizophrenia using multiple models will permit an understanding of the core features of the disease, thereby facilitating preclinical research aimed at the development and validation of better pharmacotherapies to alter the progression of schizophrenia or alleviate its debilitating symptoms.

Entities:  

Keywords:  5-hydroxytryptamine (5-HT; animal models; dopamine; glutamate; schizophrenia; serotonin)

Mesh:

Year:  2018        PMID: 29742910      PMCID: PMC6364139          DOI: 10.1177/0706743718773728

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  172 in total

1.  The NIMH Research Domain Criteria Initiative: Background, Issues, and Pragmatics.

Authors:  Michael J Kozak; Bruce N Cuthbert
Journal:  Psychophysiology       Date:  2016-03       Impact factor: 4.016

Review 2.  The NEWMEDS rodent touchscreen test battery for cognition relevant to schizophrenia.

Authors:  M Hvoslef-Eide; A C Mar; S R O Nilsson; J Alsiö; C J Heath; L M Saksida; T W Robbins; T J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2015-07-24       Impact factor: 4.530

Review 3.  D-serine and schizophrenia: an update.

Authors:  Emerson A Nunes; Erin M MacKenzie; David Rossolatos; Jorge Perez-Parada; Glen B Baker; Serdar M Dursun
Journal:  Expert Rev Neurother       Date:  2012-07       Impact factor: 4.618

4.  Blood D-serine levels as a predictive biomarker for the rapid antidepressant effects of the NMDA receptor antagonist ketamine.

Authors:  Kenji Hashimoto
Journal:  Psychopharmacology (Berl)       Date:  2014-09-05       Impact factor: 4.530

5.  Sex-specific alterations in behavioral and cognitive functions in a "three hit" animal model of schizophrenia.

Authors:  G Kekesi; Z Petrovszki; G Benedek; G Horvath
Journal:  Behav Brain Res       Date:  2015-02-16       Impact factor: 3.332

Review 6.  Neuregulin 1 in neural development, synaptic plasticity and schizophrenia.

Authors:  Lin Mei; Wen-Cheng Xiong
Journal:  Nat Rev Neurosci       Date:  2008-05-14       Impact factor: 34.870

Review 7.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Authors:  Jared W Young; Susan B Powell; Victoria Risbrough; Hugh M Marston; Mark A Geyer
Journal:  Pharmacol Ther       Date:  2009-03-06       Impact factor: 12.310

8.  Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat.

Authors:  R S Mansbach; M A Geyer
Journal:  Neuropsychopharmacology       Date:  1989-12       Impact factor: 7.853

9.  Loss of dysbindin-1 in mice impairs reward-based operant learning by increasing impulsive and compulsive behavior.

Authors:  Gregory V Carr; Kimberly A Jenkins; Daniel R Weinberger; Francesco Papaleo
Journal:  Behav Brain Res       Date:  2012-12-20       Impact factor: 3.332

10.  Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume.

Authors:  Paola Dazzan; Carmine M Pariante; Valeria Mondelli; Annamaria Cattaneo; Martino Belvederi Murri; Marta Di Forti; Rowena Handley; Nilay Hepgul; Ana Miorelli; Serena Navari; Andrew S Papadopoulos; Katherine J Aitchison; Craig Morgan; Robin M Murray
Journal:  J Clin Psychiatry       Date:  2011-05-18       Impact factor: 4.384

View more
  27 in total

1.  Haloperidol rescues the schizophrenia-like phenotype in adulthood after rotenone administration in neonatal rats.

Authors:  Thiago Garcia Varga; Juan Guilherme de Toledo Simões; Amanda Siena; Elisandra Henrique; Regina Cláudia Barbosa da Silva; Vinicius Dos Santos Bioni; Aline Camargo Ramos; Tatiana Rosado Rosenstock
Journal:  Psychopharmacology (Berl)       Date:  2021-06-05       Impact factor: 4.530

2.  Connectomic Underpinnings of Working Memory Deficits in Schizophrenia: Evidence From a replication fMRI study.

Authors:  Jie Yang; Weidan Pu; Guowei Wu; Eric Chen; Edwin Lee; Zhening Liu; Lena Palaniyappan
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

Review 3.  Stem cell-based models and therapies: a key approach into schizophrenia treatment.

Authors:  Bagher Larijani; Peyvand Parhizkar Roudsari; Mahdieh Hadavandkhani; Sepideh Alavi-Moghadam; Mostafa Rezaei-Tavirani; Parisa Goodarzi; Forough Azam Sayahpour; Fereshteh Mohamadi-Jahani; Babak Arjmand
Journal:  Cell Tissue Bank       Date:  2021-01-02       Impact factor: 1.522

Review 4.  Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia.

Authors:  Cassandra J Hatzipantelis; Monica Langiu; Teresa H Vandekolk; Tracie L Pierce; Jess Nithianantharajah; Gregory D Stewart; Christopher J Langmead
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-28

Review 5.  Leveraging genetic discoveries for sleep to determine causal relationships with common complex traits.

Authors:  Shilpa Sonti; Struan F A Grant
Journal:  Sleep       Date:  2022-10-10       Impact factor: 6.313

6.  What Can We Learn from Animal Models to Study Schizophrenia?

Authors:  Fernanda Crunfli; Caroline Brandão-Teles; Giuliana S Zuccoli; Adriano J M Chaves Filho; Gabriela Maciel Vieira; Danyelle Silva-Amaral; José Alexandre Crippa; João F C Pedrazzi; Danielle S Macêdo; Elaine Del-Bel; Felipe V Gomes
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

7.  mTOR Expression in Hippocampus and Prefrontal Cortex Is Downregulated in a Rat Model of Schizophrenia Induced by Chronic Administration of Ketamine.

Authors:  Runfang Xie; Jiming Xie; Yi Ye; Xueyan Wang; Fan Chen; Lin Yang; Youyi Yan; Linchuan Liao
Journal:  J Mol Neurosci       Date:  2020-01-02       Impact factor: 3.444

Review 8.  Asenapine Transdermal Patch for the Management of Schizophrenia.

Authors:  Maxine Zhou; Sahar Derakhshanian; Alexander Rath; Sarah Bertrand; Caroline DeGraw; Rachel Barlow; Aja Menard; Adam M Kaye; Jamal Hasoon; Elyse M Cornett; Alan D Kaye; Omar Viswanath; Ivan Urits
Journal:  Psychopharmacol Bull       Date:  2020-09-14

Review 9.  Basic and Preclinical Research for Personalized Medicine.

Authors:  Wanda Lattanzi; Cristian Ripoli; Viviana Greco; Marta Barba; Federica Iavarone; Angelo Minucci; Andrea Urbani; Claudio Grassi; Ornella Parolini
Journal:  J Pers Med       Date:  2021-04-29

10.  Maternal immune activation as a risk factor for psychiatric illness in the context of the SARS-CoV-2 pandemic.

Authors:  Brittney Lins
Journal:  Brain Behav Immun Health       Date:  2021-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.